OptiBiotix Health PLC Appointment of a Chairman for SkinBiotix (6849L)
October 05 2016 - 2:00AM
UK Regulatory
TIDMOPTI
RNS Number : 6849L
OptiBiotix Health PLC
05 October 2016
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Appointment of Chairman and Director for SkinBiotix Limited
OptiBiotix Health plc (AIM:OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces the appointment of Martin Hunt as Chairman
and Director of its majority owned subsidiary SkinBiotix Limited
("SkinBiotix").
SkinBiotix is dedicated to the development of skin
biotherapeutics using natural components of the skin microbiome to
manage and protect against skin health problems. SkinBiotix uses
patented technology to address health issues in the Cosmetic Skin
Care ($121bn); Acquired Skin Infections ($82bn); Dermatology
($10.2bn); and Wound Care ($18bn) markets.
Martin brings a wealth of experience and a track record of
success in leadership and strategic roles within the life sciences
sector, spanning large multi-nationals, AIM listed plc's, early
stage ventures and public sector roles. His experience at MDY
Healthcare Limited, Videregen Limited, Oxford Medical Diagnostics
Limited and his roles at the National Institute for Health Research
give him that broad range of understanding of the wide ranging
commercial and therapeutic area which SkinBiotix will be working
in.
Martin's appointment brings experience and dedicated leadership
to SkinBiotix to help build a team to fully exploit opportunities
in the skin microbiome space. This includes plans for Optibiotix to
demerge its SkinBiotix division and seek an Initial Public
Offering. This is in line with OptiBiotix's strategy announced in
July of this year. In that announcement OptiBiotix outlined its
belief that the diversity of IP and commercial relationships across
its four divisions offered shareholders multiple opportunities
where future value to shareholders may be best realised by spinning
out domain specific opportunities.
Stephen O'Hara, CEO of OptiBiotix, commented: "Martin brings a
proven record across life sciences as a CEO and Chairman and we are
delighted that he has joined SkinBiotix at this exciting stage of
its development. OptiBiotix believes the scale of the opportunities
offered by SkinBiotix's intellectual property in the skin
biotherapeutic space means that this can best be achieved by a
separate leadership and listing. This will provide the domain
specific expertise and resources to ensure the opportunities
provided by this exciting technology can be fully realised."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via
Walbrook below
Cairn Financial Advisers LLP Tel: 020 7148
7900
Liam Murray
finnCap Broker Tel: 020 7220
0500
Adrian Hargrave / Scott Mathieson
/ Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or
optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741
001
Mike Wort Mob: 07900 608
002
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCZMMGGKDGGVZM
(END) Dow Jones Newswires
October 05, 2016 02:00 ET (06:00 GMT)